
    
      Flexible dosing up to 200 mg/day, twice daily (10, 25 and 50 mg oral film-coated tablets).
      The study will continue until either regulatory approval of BRV has been granted by any
      Health Authority in an indication of adjunctive treatment of Epilepsy, or until the Sponsor
      decides to close the study, or until the BRV development is stopped by the Sponsor.
    
  